5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Mortality O
: O
There O
were O
more O
deaths O
reported O
with O
BENLYSTA O
than O
with O
placebo O
during O
the O
controlled O
period O
of O
clinical O
trials O
. O

( O
5.1 O
) O
* O
Serious O
Infections O
: O
Serious O
and O
sometimes O
fatal O
infections O
have O
been O
reported O
in O
patients O
receiving O
immunosuppressive O
agents O
, O
including O
BENLYSTA O
. O

Use O
with O
caution O
in O
patients O
with O
severe O
or O
chronic O
infections O
. O

Consider O
interrupting O
therapy O
with O
BENLYSTA O
if O
patients O
develop O
a O
new O
infection O
during O
treatment O
with O
BENLYSTA O
. O

( O
5.2 O
) O
* O
Progressive O
Multifocal O
Leukoencephalopathy O
( O
PML O
) O
: O
Patients O
presenting O
with O
new-onset O
or O
deteriorating O
neurological O
signs O
and O
symptoms O
should O
be O
evaluated O
for O
PML O
by O
an O
appropriate O
specialist O
. O

If O
PML O
is O
confirmed O
, O
consider O
discontinuation O
of O
immunosuppressant O
therapy O
, O
including O
BENLYSTA O
. O

( O
5.2 O
) O
* O
Hypersensitivity O
Reactions O
, O
including O
Anaphylaxis O
: O
Serious O
and O
fatal O
reactions O
have O
been O
reported O
. O

BENLYSTA O
for O
intravenous O
use O
should O
be O
administered O
by O
healthcare O
providers O
prepared O
to O
manage O
anaphylaxis O
. O

Monitor O
patients O
during O
and O
for O
an O
appropriate O
period O
of O
time O
after O
intravenous O
administration O
of O
BENLYSTA O
. O

( O
2.1 O
, O
5.3 O
) O
* O
Depression O
: O
Depression O
and O
suicidality O
have O
been O
reported O
in O
trials O
with O
BENLYSTA O
. O

Patients O
should O
be O
instructed O
to O
contact O
their O
healthcare O
provider O
if O
they O
experience O
new O
or O
worsening O
depression O
, O
suicidal O
thoughts O
, O
or O
other O
mood O
changes O
. O

( O
5.5 O
) O
* O
Immunization O
: O
Live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
BENLYSTA O
. O

( O
5.7 O
) O
5.1 O
Mortality O
There O
were O
more O
deaths B-NonOSE_AE
reported O
with O
BENLYSTA O
than O
with O
placebo O
during O
the O
controlled O
period O
of O
the O
intravenous O
clinical O
trials O
. O

Out O
of O
2,133 O
patients O
in O
3 O
clinical O
trials O
, O
a O
total O
of O
14 O
deaths B-NonOSE_AE
occurred O
during O
the O
placebo-controlled O
, O
double-blind O
treatment O
periods O
: O
3/675 O
( O
0.4 O
% O
) O
, O
5/673 O
( O
0.7 O
% O
) O
, O
0/111 O
( O
0 O
% O
) O
, O
and O
6/674 O
( O
0.9 O
% O
) O
deaths B-NonOSE_AE
in O
the O
groups O
receiving O
placebo O
, O
BENLYSTA O
1 O
mg/kg O
, O
BENLYSTA O
4 O
mg/kg O
, O
and O
BENLYSTA O
10 O
mg/kg O
, O
respectively O
. O

No O
single O
cause O
of O
death B-NonOSE_AE
predominated O
. O

Etiologies O
included O
infection B-NonOSE_AE
, O
cardiovascular B-NonOSE_AE
disease I-NonOSE_AE
, O
and O
suicide B-NonOSE_AE
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
a O
total O
of O
5 O
deaths B-NonOSE_AE
occurred O
during O
the O
placebo-controlled O
, O
double-blind O
treatment O
period O
( O
0.7 O
% O
[ O
2/280 O
] O
of O
patients O
receiving O
placebo O
and O
0.5 O
% O
[ O
3/556 O
] O
of O
patients O
receiving O
BENLYSTA O
) O
. O

Infection B-NonOSE_AE
was O
the O
most O
common O
cause O
of O
death B-NonOSE_AE
. O

5.2 O
Serious O
Infections O
Serious O
and O
sometimes O
fatal B-NonOSE_AE
infections B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
, O
including O
BENLYSTA O
. O

Physicians O
should O
exercise O
caution O
when O
considering O
the O
use O
of O
BENLYSTA O
in O
patients O
with O
severe O
or O
chronic O
infections B-Not_AE_Candidate
. O

Consider O
interrupting O
therapy O
with O
BENLYSTA O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
while O
undergoing O
treatment O
with O
BENLYSTA O
and O
monitor O
these O
patients O
closely O
. O

In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
the O
overall O
incidence O
of O
infections B-OSE_Labeled_AE
was O
71 O
% O
in O
patients O
treated O
with O
BENLYSTA O
compared O
with O
67 O
% O
in O
patients O
who O
received O
placebo O
. O

The O
most O
frequent O
infections B-OSE_Labeled_AE
( O
> O
5 O
% O
of O
patients O
receiving O
BENLYSTA O
) O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
influenza B-OSE_Labeled_AE
. O

Serious O
infections B-OSE_Labeled_AE
occurred O
in O
6.0 O
% O
of O
patients O
treated O
with O
BENLYSTA O
and O
in O
5.2 O
% O
of O
patients O
who O
received O
placebo O
. O

The O
most O
frequent O
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
and O
bronchitis B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
leading O
to O
discontinuation O
of O
treatment O
occurred O
in O
0.7 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
1.0 O
% O
of O
patients O
receiving O
placebo O
. O

Infections B-OSE_Labeled_AE
resulting O
in O
death B-NonOSE_AE
occurred O
in O
0.3 O
% O
( O
4/1,458 O
) O
of O
patients O
treated O
with O
BENLYSTA O
and O
in O
0.1 O
% O
( O
1/675 O
) O
of O
patients O
receiving O
placebo O
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
the O
overall O
incidence O
of O
infections B-NonOSE_AE
was O
55 O
% O
in O
patients O
treated O
with O
BENLYSTA O
compared O
with O
57 O
% O
in O
patients O
who O
received O
placebo O
( O
serious O
infections B-NonOSE_AE
: O
4.1 O
% O
with O
BENLYSTA O
and O
5.4 O
% O
with O
placebo O
) O
. O

The O
most O
commonly O
reported O
infections B-NonOSE_AE
with O
BENLYSTA O
administered O
subcutaneously O
were O
similar O
to O
those O
reported O
with O
BENLYSTA O
administered O
intravenously O
. O

Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
Cases O
of O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
PML B-OSE_Labeled_AE
resulting O
in O
neurological B-NonOSE_AE
deficits I-NonOSE_AE
, O
including O
fatal B-NonOSE_AE
cases O
, O
have O
been O
reported O
in O
patients O
with O
SLE B-Not_AE_Candidate
receiving O
immunosuppressants B-NonOSE_AE
, O
including O
BENLYSTA O
. O

Risk O
factors O
for O
PML B-NonOSE_AE
include O
treatment O
with O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
and O
impairment B-NonOSE_AE
of I-NonOSE_AE
immune I-NonOSE_AE
function I-NonOSE_AE
. O

Consider O
the O
diagnosis O
of O
PML B-NonOSE_AE
in O
any O
patient O
presenting O
with O
new-onset O
or O
deteriorating O
neurological B-NonOSE_AE
signs I-NonOSE_AE
and O
symptoms O
and O
consult O
with O
a O
neurologist O
or O
other O
appropriate O
specialist O
as O
clinically O
indicated O
. O

In O
patients O
with O
confirmed O
PML B-NonOSE_AE
, O
consider O
stopping O
immunosuppressant B-NonOSE_AE
therapy I-NonOSE_AE
, O
including O
BENLYSTA O
. O

5.3 O
Hypersensitivity O
Reactions O
, O
including O
Anaphylaxis O
Acute O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
anaphylaxis B-OSE_Labeled_AE
and O
death B-NonOSE_AE
, O
have O
been O
reported O
in O
association O
with O
BENLYSTA O
. O

These O
events O
generally O
occurred O
within O
hours O
of O
the O
infusion O
; O
however O
, O
they O
may O
occur O
later O
. O

Non-acute O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
have O
been O
reported O
and O
typically O
occurred O
up O
to O
a O
week O
following O
the O
most O
recent O
infusion O
. O

Hypersensitivity B-OSE_Labeled_AE
, O
including O
serious O
reactions O
, O
has O
occurred O
in O
patients O
who O
have O
previously O
tolerated O
infusions O
of O
BENLYSTA O
. O

Limited O
data O
suggest O
that O
patients O
with O
a O
history O
of O
multiple O
drug B-Not_AE_Candidate
allergies I-Not_AE_Candidate
or O
significant O
hypersensitivity B-Not_AE_Candidate
may O
be O
at O
increased O
risk O
. O

In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
occurring O
on O
the O
same O
day O
of O
infusion O
) O
were O
reported O
in O
13 O
% O
( O
191/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
11 O
% O
( O
76/675 O
) O
of O
patients O
receiving O
placebo O
. O

Anaphylaxis B-OSE_Labeled_AE
was O
observed O
in O
0.6 O
% O
( O
9/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
0.4 O
% O
( O
3/675 O
) O
of O
patients O
receiving O
placebo O
. O

Manifestations O
included O
hypotension B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
urticaria B-NonOSE_AE
or O
other O
rash B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
and O
dyspnea B-NonOSE_AE
. O

Due O
to O
overlap O
in O
signs O
and O
symptoms O
, O
it O
was O
not O
possible O
to O
distinguish O
between O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
in O
all O
cases O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Some O
patients O
( O
13 O
% O
) O
received O
premedication O
, O
which O
may O
have O
mitigated O
or O
masked O
a O
hypersensitivity B-NonOSE_AE
response O
; O
however O
, O
there O
is O
insufficient O
evidence O
to O
determine O
whether O
premedication O
diminishes O
the O
frequency O
or O
severity O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
. O

BENLYSTA O
for O
intravenous O
use O
should O
be O
administered O
by O
healthcare O
providers O
prepared O
to O
manage O
anaphylaxis B-NonOSE_AE
. O

In O
the O
event O
of O
a O
serious O
reaction O
, O
administration O
of O
BENLYSTA O
must O
be O
discontinued O
immediately O
and O
appropriate O
medical O
therapy O
administered O
. O

Patients O
should O
be O
monitored O
during O
and O
for O
an O
appropriate O
period O
of O
time O
after O
intravenous O
administration O
of O
BENLYSTA O
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
systemic O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
were O
similar O
to O
those O
observed O
in O
the O
intravenous O
clinical O
trials O
. O

Patients O
receiving O
BENLYSTA O
should O
be O
informed O
of O
the O
signs O
and O
symptoms O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
and O
be O
instructed O
to O
seek O
immediate O
medical O
care O
should O
a O
reaction O
occur O
. O

5.4 O
Infusion O
Reactions O
In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
adverse B-OSE_Labeled_AE
events I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
( O
occurring O
on O
the O
same O
day O
of O
the O
infusion O
) O
were O
reported O
in O
17 O
% O
( O
251/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
15 O
% O
( O
99/675 O
) O
of O
patients O
receiving O
placebo O
. O

Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
excluding O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
) O
were O
reported O
in O
0.5 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
and O
included O
bradycardia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
hypotension B-OSE_Labeled_AE
. O

The O
most O
common O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
> O
=3 O
% O
of O
patients O
receiving O
BENLYSTA O
) O
were O
headache B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Due O
to O
overlap O
in O
signs O
and O
symptoms O
, O
it O
was O
not O
possible O
to O
distinguish O
between O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
in O
all O
cases O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Some O
patients O
( O
13 O
% O
) O
received O
premedication O
, O
which O
may O
have O
mitigated O
or O
masked O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
; O
however O
, O
there O
is O
insufficient O
evidence O
to O
determine O
whether O
premedication O
diminishes O
the O
frequency O
or O
severity O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

BENLYSTA O
for O
intravenous O
use O
should O
be O
administered O
by O
healthcare O
providers O
prepared O
to O
manage O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

The O
infusion O
rate O
may O
be O
slowed O
or O
interrupted O
if O
the O
patient O
develops O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
. O

Healthcare O
providers O
should O
be O
aware O
of O
the O
risk O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
, O
which O
may O
present O
as O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
and O
monitor O
patients O
closely O
. O

5.5 O
Depression O
In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
psychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
more O
frequently O
with O
BENLYSTA O
( O
16 O
% O
) O
than O
with O
placebo O
( O
12 O
% O
) O
, O
related O
primarily O
to O
depression B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
6.3 O
% O
BENLYSTA O
and O
4.7 O
% O
placebo O
) O
, O
insomnia B-OSE_Labeled_AE
( O
6.0 O
% O
BENLYSTA O
and O
5.3 O
% O
placebo O
) O
, O
and O
anxiety B-OSE_Labeled_AE
( O
3.9 O
% O
BENLYSTA O
and O
2.8 O
% O
placebo O
) O
. O

Serious O
psychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
0.8 O
% O
of O
patients O
receiving O
BENLYSTA O
( O
0.6 O
% O
and O
1.2 O
% O
with O
1 O
and O
10 O
mg/kg O
, O
respectively O
) O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
. O

Serious O
depression B-OSE_Labeled_AE
was O
reported O
in O
0.4 O
% O
( O
6/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
0.1 O
% O
( O
1/675 O
) O
of O
patients O
receiving O
placebo O
. O

Two O
suicides B-OSE_Labeled_AE
( O
0.1 O
% O
) O
were O
reported O
in O
patients O
receiving O
BENLYSTA O
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
psychiatric B-NonOSE_AE
events I-NonOSE_AE
were O
reported O
in O
6 O
% O
of O
patients O
treated O
with O
BENLYSTA O
and O
in O
11 O
% O
of O
patients O
who O
received O
placebo O
. O

Depression B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
events I-NonOSE_AE
were O
reported O
in O
2.7 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
3.6 O
% O
of O
patients O
receiving O
placebo O
. O

Serious O
psychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
0.2 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
in O
no O
patients O
receiving O
placebo O
. O

There O
were O
no O
serious O
depression B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
events I-NonOSE_AE
or O
suicides B-NonOSE_AE
reported O
in O
either O
group O
. O

The O
majority O
of O
patients O
who O
reported O
serious O
depression B-NonOSE_AE
or O
suicidal B-NonOSE_AE
behavior I-NonOSE_AE
had O
a O
history O
of O
depression B-Not_AE_Candidate
or O
other O
serious O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
most O
were O
receiving O
psychoactive O
medications O
. O

It O
is O
unknown O
if O
treatment O
with O
BENLYSTA O
is O
associated O
with O
increased O
risk O
for O
these O
events O
. O

Patients O
receiving O
BENLYSTA O
should O
be O
instructed O
to O
contact O
their O
healthcare O
provider O
if O
they O
experience O
new O
or O
worsening O
depression B-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
, O
or O
other O
mood B-NonOSE_AE
changes I-NonOSE_AE
. O

5.6 O
Malignancy O
The O
impact O
of O
treatment O
with O
BENLYSTA O
on O
the O
development O
of O
malignancies B-NonOSE_AE
is O
not O
known O
. O

In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
malignancies B-NonOSE_AE
( O
including O
non B-NonOSE_AE
- I-NonOSE_AE
melanoma I-NonOSE_AE
skin I-NonOSE_AE
cancers I-NonOSE_AE
) O
were O
reported O
in O
0.4 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
. O

In O
the O
intravenous O
controlled O
clinical O
trials O
, O
malignancies B-NonOSE_AE
, O
excluding O
non B-NonOSE_AE
- I-NonOSE_AE
melanoma I-NonOSE_AE
skin I-NonOSE_AE
cancers I-NonOSE_AE
, O
were O
observed O
in O
0.2 O
% O
( O
3/1,458 O
) O
and O
0.3 O
% O
( O
2/675 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
placebo O
, O
respectively O
. O

In O
the O
controlled O
clinical O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
the O
data O
were O
similar O
. O

The O
mechanism O
of O
action O
of O
BENLYSTA O
could O
increase O
the O
risk O
for O
the O
development O
of O
malignancies B-OSE_Labeled_AE
. O

5.7 O
Immunization O
Live O
vaccines O
should O
not O
be O
given O
for O
30 O
days O
before O
or O
concurrently O
with O
BENLYSTA O
as O
clinical O
safety O
has O
not O
been O
established O
. O

No O
data O
are O
available O
on O
the O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
from O
persons O
receiving O
live O
vaccines O
to O
patients O
receiving O
BENLYSTA O
or O
the O
effect O
of O
BENLYSTA O
on O
new O
immunizations O
. O

Because O
of O
its O
mechanism O
of O
action O
, O
BENLYSTA O
may O
interfere B-OSE_Labeled_AE
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
response I-OSE_Labeled_AE
to I-OSE_Labeled_AE
immunizations I-OSE_Labeled_AE
. O

5.8 O
Concomitant O
Use O
with O
Other O
Biologic O
Therapies O
or O
Intravenous O
Cyclophosphamide O
BENLYSTA O
has O
not O
been O
studied O
in O
combination O
with O
other O
biologic O
therapies O
, O
including O
B-cell O
targeted O
therapies O
, O
or O
intravenous O
cyclophosphamide O
. O

Therefore O
, O
use O
of O
BENLYSTA O
is O
not O
recommended O
in O
combination O
with O
biologic O
therapies O
or O
intravenous O
cyclophosphamide O
. O

